Podcasts about Friedberg

John Johnston (JJ) reacts to part of a recent episode of the All-In Podcast with the tech billionaire “Besties”, Chamath, Jason, David Sacks, and Friedberg, in relation to what politician Bernie Sanders is currently saying about AI sector development. Senator Sanders is proposing an AI data center moratorium, and is critical of the tech billionaires involved. The All-in Besties explain why they think this is just fearmongering, and think the tech sector needs to frame fast AI development in a more positive way. Related episodes:Why All-In Podcast Tech Billionaires Don't Get the AI Backlash (ft. Tucker Carlson) https://open.spotify.com/episode/3vOcht7oeoJGu9nqevtT98Sam Harris & Kara Swisher on Elon Musk: Techno-Authoritarianism and "Maniac" Behavior https://open.spotify.com/episode/0jEONT8ErTK2NFc5ObLmhJElon MUSK'S xAI Grok si POISONING Memphis! https://open.spotify.com/episode/2hAAzu6bIiBQpkSSmkZPhsReferenced videos:Bernie Sanders: Stop All AI, China's EUV Breakthrough, Inflation Down, Golden Age in 2026? | All-In Podcast https://open.spotify.com/episode/26BF1wvIwGuic4lYhWuBfhIt's Time for a Moratorium on Data Centers | Sen. Bernie Sanders https://youtu.be/f40SFNcTOXo

John Johnston (JJ) reacts to part of a recent episode of the All-In Podcast with the tech billionaire “Besties”, Chamath, Jason, David Sacks, and Friedberg, in relation to what politician Bernie Sanders is currently saying about AI sector development. Senator Sanders is proposing an AI data center moratorium, and is critical of the tech billionaires involved. The All-in Besties explain why they think this is just fearmongering, and think the tech sector needs to frame fast AI development in a more positive way. Related episodes:Why All-In Podcast Tech Billionaires Don't Get the AI Backlash (ft. Tucker Carlson) https://open.spotify.com/episode/3vOcht7oeoJGu9nqevtT98Sam Harris & Kara Swisher on Elon Musk: Techno-Authoritarianism and "Maniac" Behavior https://open.spotify.com/episode/0jEONT8ErTK2NFc5ObLmhJElon MUSK'S xAI Grok si POISONING Memphis! https://open.spotify.com/episode/2hAAzu6bIiBQpkSSmkZPhsReferenced videos:Bernie Sanders: Stop All AI, China's EUV Breakthrough, Inflation Down, Golden Age in 2026? | All-In Podcast https://open.spotify.com/episode/26BF1wvIwGuic4lYhWuBfhIt's Time for a Moratorium on Data Centers | Sen. Bernie Sanders https://youtu.be/f40SFNcTOXo

Unbekannte brechen früh mit einem Fahrzeug in ein Fahrradgeschäft in Friedberg ein und klauen mindestens 10 Räder. Hochschulpakt zwingt auch Technische Hochschule Mittelhessen zu Kürzungen

JCO Editor-in-Chief Dr. Jonathan Friedberg is joined by colleagues Dr. Jennifer Woyach, Dr. Wojciech Jurczak, and Dr. Matthew Davids to discuss simultaneous publications presented at ASH 2025 on pertibrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Jonathan Friedberg: I'm Jonathan Friedberg, editor of Journal of Clinical Oncology, and welcome to JCO After Hours, where we are covering two manuscripts that were presented at the American Society of Hematology meeting 2025 in Orlando, Florida. I am delighted to be joined by colleagues on this call to discuss these pivotal manuscripts which cover the topic of pirtobrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. I will first just introduce our guests, Dr. Woyach. Dr. Jennifer Woyach: Hi, my name is Jennifer Woyach. I am from the Ohio State University. Dr. Wojciech Jurczak: Hello, I am Wojciech Jurczak, working at the National Research Institute of Oncology in Krakow, Poland. Dr. Matthew Davids: Hi, I am Matthew Davids from Dana-Farber Cancer Institute in Boston. Dr. Jonathan Friedberg: We are going to start by just learning a little bit about these two trials that were both large, randomized phase 3 studies that I think answered some definitive questions. We will start with your study, Jennifer. If you could just describe the design of your study and the patient population. Dr. Jennifer Woyach: Absolutely. So this is the BRUIN CLL-314 study, and this is a phase 3 randomized trial of pirtobrutinib versus ibrutinib in patients with CLL or SLL who had not previously been treated with a covalent BTK inhibitor. The patients were both treatment-naive and relapsed/refractory, about one-third of the patients treatment-naive, the rest relapsed/refractory, and they were stratified based upon 17p deletion and the number of prior lines of therapy. The primary objective was looking at non-inferiority of overall response rate over the entire treated population as well as the relapsed/refractory patient population. Key secondary objectives included progression-free survival in the intention-to-treat and the smaller relapsed/refractory and treatment-naive populations. Dr. Jonathan Friedberg: And just comment a little bit on the risk of the patients. Dr. Jennifer Woyach: This study was fairly typical of this cohort of patients. Within the relapsed/refractory patient population, there was a median of one prior line of therapy in each of the groups, up to nine prior lines of therapy in the patients included on the study. For the overall cohort, about two-thirds of the patients were IGHV unmutated, about 15% had 17p deletion, 30% had TP53 mutations, and about 35% to 40% had a complex karyotype, which is three or more abnormalities. Dr. Jonathan Friedberg: And what were your findings? Dr. Jennifer Woyach: Regarding the primary outcome, which is the focus of the publication, we did find that pirtobrutinib was indeed non-inferior and actually superior to ibrutinib for overall response rate throughout the entire patient population and in both the relapsed/refractory and treatment-naive cohorts. PFS is a little bit immature at this time but is trending towards also being significantly better in pirtobrutinib-treated patients compared with ibrutinib-treated patients. Probably most significantly, we found this to be the case in the treatment-naive cohort where there was a striking trend to an advantage of pirtobrutinib versus ibrutinib. Dr. Jonathan Friedberg: And the follow-up that you have on that progression-free survival? Dr. Jennifer Woyach: So we have about 18 months follow-up on progression-free survival. Dr. Jonathan Friedberg: The second study, Wojciech, can you just go through the design and patient population that you treated? Dr. Wojciech Jurczak: Thank you, Dr. Friedberg, for this question. So the BRUIN CLL-313 study was, in fact, the first phase 3 study with pirtobrutinib in exclusively untreated CLL patients. It was a randomized study where we challenged pirtobrutinib versus bendamustine-rituximab. At the time we designed the protocol, bendamustine-rituximab was an option as a standard of care, and Bruton tyrosine kinase monotherapy was used far more commonly than nowadays. The primary target of the study was progression-free survival. We took all untreated patients except for those with 17p deletions. Therefore, it is a good representation for intermediate risk. We had about 60% of the population, 56 to be precise, which was unmutated, evenly distributed into two treatment arms. 17p deleted cases were excluded, but we had about 7% and 8% of TP53 mutated patients as well as about 11% and 7%, respectively, in the pirtobrutinib and bendamustine-rituximab arm of patients with complex karyotype. The progression-free survival was in favor of pirtobrutinib and was assessed by an independent review committee. What is important is that the progression-free survival of the bendamustine-rituximab arm was actually similar to the other studies addressing the same questions, like the comparison with ibrutinib in the ALLIANCE study or zanubrutinib in the SEQUOIA study. What was different was the hazard ratio. In our study, it was 0.20. It was one of the longest effect sizes noted in the frontline BTK study. It represented an 80% reduction in progression-free survival or death. If we compare it to ibrutinib or zanubrutinib, it was 0.39 and 0.42 respectively. Presumably, this great effect contributed towards a trend of overall survival difference. Although survival data are not mature enough, there is a clear trend represented by three patients we lost in the pirtobrutinib arm versus 10 patients lost in the bendamustine-rituximab arm. This trend in overall survival is becoming statistically significant despite the fact that there was a possibility of crossover, and effectively 52.9 patients, which means 18 out of 34 patients relapsing in the bendamustine-rituximab arm, were treated by pirtobrutinib. Dr. Jonathan Friedberg: I am going to turn it over to Matt. The question is: why study pirtobrutinib in this patient population? And then with these two studies, how do you find the patients that were treated, are they representative of people who you see? And do you see this maybe being approved and more widely available? Dr. Matthew Davids: I think in terms of the first question, why study this in a frontline population, we have seen very impressive data with pirtobrutinib in a very difficult-to-treat population of CLL patients. This was from the original BRUIN phase 1/2 study where most of the patients had at least two or three lines of therapy, often both a covalent BTK inhibitor and the BCL2 inhibitor venetoclax, and yet they were still responding to pirtobrutinib. The drug was also very well tolerated in that early phase experience. And actually, we have seen phase 3 data from the BRUIN 321 study comparing pirtobrutinib to bendamustine and rituximab in a relapse population as well. So I think that really motivated these studies to look at pirtobrutinib as a first therapy. You know, often in other cancers of course, we want to use our best therapy first, and I think these studies are an initial step at looking at that. In terms of the second question around the patient population, these are pretty representative patient populations, I would say, for most frontline CLL studies. We see patients who are a bit younger and fitter than sort of the general population of CLL patients who are treated in clinical practice, and I think that is true here as well. Median age in the sort of mid-60s here is a bit younger than the typical patients we are treating in practice. But that is not different from other CLL frontline studies that we have seen recently, so I think it makes it a little bit easier as we kind of think across studies to feel comfortable that these are relatively similar populations. Dr. Jonathan Friedberg: How do you see this either getting regulatory approval or potentially being used compared to current standard of care options? Dr. Matthew Davids: So my understanding is that both of these trials were designed with registrational intent in the frontline setting, and they are both positive studies. That is certainly very encouraging in terms of the potential for an approval here. We have seen in terms of the FDA recently some concerns around the proportion of patients who are coming from North America, and my understanding is that is relatively low on these two studies. But nonetheless, the datasets are very impressive, and so I think it is certainly supportive of regulatory approval for frontline pirtobrutinib. Dr. Jonathan Friedberg: I will ask Jennifer a question. The control arm in your study was ibrutinib, and I think many in the audience may recognize that newer, second-generation BTK inhibitors like acalabrutinib and zanubrutinib are more frequently used now if monotherapy is decided. How do you respond to that, and how would you put your results in your pirtobrutinib arm in context with what has been observed with those agents? Dr. Jennifer Woyach: Yeah, that is a great question. Even though in the United States we are predominantly using acalabrutinib or zanubrutinib when choosing a monotherapy BTK inhibitor, this is actually not the case throughout the entire world where ibrutinib is still used very frequently. The head-to-head studies of both acalabrutinib and zanubrutinib compared to ibrutinib have shown us pretty well what the safety profile and efficacy profile of the second-generation BTK inhibitors is. So even though we do not have a head-to-head study of acalabrutinib or zanubrutinib versus pirtobrutinib, I think, given the entirety of data that we have with all of the covalent BTK inhibitors, I think we can safely look at the pirtobrutinib arm here, how the ibrutinib arm compares or performs in context with those other clinical trials. And though we really can not say anything about pirtobrutinib versus acalabrutinib or zanubrutinib, I think we can still get a good idea of what might be the clinical scenarios in which you might want to choose pirtobrutinib. Dr. Jonathan Friedberg: And Wojciech, do you agree with that? Obviously, I think you have acknowledged that chemoimmunotherapy is rarely used anymore as part of upfront treatment for CLL. So, I guess a similar question. If you were to put the pirtobrutinib result in your study in context with, I guess, more contemporary type controls, would you agree that it is competitive? Dr. Wojciech Jurczak: Well, I think that that was the last study ever where bendamustine-rituximab was used as a comparator arm. So we should notice that smashing difference. Because if we look at the progression-free survival at two years, we have 93.4% in pirtobrutinib arm versus 70.7% in bendamustine-rituximab arm. Bendamustine-rituximab arm did the same as in the other trials, like ALLIANCE or SEQUOIA. Pirtobrutinib did exceptionally well, as pirto is not just the very best BTK inhibitor overcoming the resistance, but perhaps even more important for the first line, it is very well tolerated and is a very selective drug. Now, if we look at treatment-related adverse events, the discontinuation rate, they were hardly ever seen. If we compared the adverse events in exposure-adjusted incidence, literally all adverse events were two or three times higher in bendamustine-rituximab arm except for the bleeding tendency, which however was predominantly in CTCAE grade 1 and 2 with just 0.7% of grade 3 hemorrhage. Therefore, I think that we should actually put the best and the safest drugs upfront if we may, and pirtobrutinib is, or should be, the first choice if we choose monotherapy. Now, I understand that we are not presenting you the data of pirtobrutinib in combination with anti-CD20 or with BCL2 inhibitors, but that is to come. Dr. Jonathan Friedberg: Matt, how would you envision, were regulatory approval granted and this were an option, using this in the upfront patient population? Is there anybody who you would preferentially use this or start on this treatment? Or would this be something that you would tend to reserve for second line? Dr. Matthew Davids: So I would say that in general for most of my patients who would want to start with a continuous BTK inhibitor, I would still use a covalent BTK inhibitor, and I say that for a couple of reasons despite the very promising data from these studies. The first is that the follow-up for both of these phase 3 trials is still quite short, in the range of a median 18 to 24 months. And we know that CLL is a marathon, not a sprint, and these patients are going to probably be living for a very long time. And we do have much longer follow-up from the covalent BTK inhibitors, median of 10-year follow-up with ibrutinib and five to six years with zanubrutinib and acalabrutinib respectively. And you know, I do not think that the pirtobrutinib is going to fall off a cliff after two years, but on the other hand, I think there is a lot of value to long-term data in this disease, and that is why I think for most of my patients I would stick with covalent BTK inhibitors. But the other important factor that we need to consider is patients who are younger and may have many different CLL treatments over the years. We have to be very careful, I think, about how we sequence these drugs. We know right now that we can start with covalent BTK inhibitors and then subsequently patients will respond well to the non-covalent inhibitor pirtobrutinib in later lines of therapy. But right now we do not have prospective data the other way around. So how will the patients on these studies who progress on pirtobrutinib respond to covalent BTK inhibitors? We do not know yet. There have not been a lot of progression events, which is great, but we would like to see some data in that respect to feel more comfortable with that sequence. Now, I do think that particularly for older patients and those who have significant cardiovascular comorbidities, if they wanted to go on a continuous BTK inhibitor, I do think these data really strongly support using pirtobrutinib as the BTK inhibitor of choice in that population. In particular, the cardiovascular risks with pirtobrutinib seem to be quite low. I was very struck in the comparison with BR that the rate of AFib was equivalent between the two arms of the study. And that is really the first time we have seen that with any of these BTK inhibitors, no elevated risk of AFib in a randomized study. I think that is the population where it will get the most traction first, is the upfront, sort of older patient with significant cardiovascular comorbidities. And as the data from these studies mature, I think that we will start to see more widespread use of pirtobrutinib in the frontline setting. Dr. Jonathan Friedberg: Jennifer, I am just curious if you have any personal experience or heard anecdotally about after progression on pirtobrutinib the use of other BTK inhibitors and whether there is a growing experience there. Dr. Jennifer Woyach: I do not think that there is much clinical experience, you know, as Matt alluded to, it certainly has not been tested yet. There has been some data in relapsed CLL suggesting that in people who have resistance mutations to covalent BTK inhibitors after treatment with pirtobrutinib, sometimes those mutations go away. I think most of us are concerned that they are probably not actually gone but maybe in compartments that we just have not sampled, suggesting that sort of approach where you might sequence a covalent inhibitor after a non-covalent in somebody who had already been resistant probably would not work that well. But, you know, in this setting where people had never been exposed to a covalent BTK inhibitor before, we really have no idea what the resistance patterns are going to be like. We assume they will be the same as what we have seen in relapsed CLL, but I think we just need some longer follow-up to know for sure. Dr. Wojciech Jurczak: If I may confront Dr. Davids about the use of covalent BTK inhibitors upfront, well, I think that we should abandon the idea of using the first and the second and the third generation, at least if we don't have medical lines. If we endlessly block the same pathway, it is not going to be effective. So if pirtobrutinib gets approval in first, second line, we do not necessarily have to use it in the first line. I am not here in a position to defend that we should treat patients with pirtobrutinib upfront and not BCL2 time-limited regimen. However, the way I look at CLL patients when choosing therapy is not just how should I treat them now, but what would be the best regimen in 5, 10 years if I have to re-treat them. And in some instances, the idea may be that in this setting we would like to have a BTK inhibitor upfront to have a BCL2 inhibitor later to make it time-limited. Although I understand and I agree with Matthew that if we have an elderly, fragile population, then the charm of having a drug taken once a day in a tablet with literally few cardiovascular adverse events might be an option. Dr. Jonathan Friedberg: And I will give Matt the last word whether he wants to respond to that, and also just as a forward-looking issue, I know both investigators have implied that there will be future studies looking at combinations with pirtobrutinib, and if you have any sense as to what you would be looking for there. Dr. Matthew Davids: The field really is heading toward time-limited therapy for most patients, I would say. There is a bit of a discrepancy right now in the field between sort of what we are doing in academic practice and what is done sort of more widely in community practice. And so right now we are going to see evolving datasets comparing these approaches. We are already seeing data now from the CLL17 study with ibrutinib comparing continuous to time-limited venetoclax-based therapy, and we are seeing similar efficacy benefits from these time-limited therapies without the need for continuous treatment. And so that is where I think some of the future studies with pirtobrutinib combining it with venetoclax and other partners are so important. Fortunately, several of these studies are already ongoing, including a phase 3 trial called CLL18, which is looking at pirtobrutinib with venetoclax, comparing that to venetoclax and obinutuzumab. So I am optimistic that we are going to be developing these very robust datasets where we can actually use pirtobrutinib in the frontline setting as a time-limited therapy as a component of a multi-drug regimen. So far, those early data are very promising. Dr. Wojciech Jurczak: Perhaps last but not least, in a single center we have treated over 300 patients with pirtobrutinib. So eventually some of them relapsed. And I must say that our experience on BCL2 inhibitors, not just venetoclax but including sonrotoclax, are appealingly good. Therefore, by using pirtobrutinib even earlier, we do not block the efficacy of other compounds. Dr. Jonathan Friedberg: All right. Well, I want to thank all of our speakers. I also want to congratulate our two guests who presented these very influential papers at the ASH Annual Meeting, and chose to publish them in JCO, so we thank you for that, and Dr. Davids for your commentary - really appreciated. That is this episode of JCO After Hours. Thank you for your attention. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Disclosures Dr. Wojciech Jurczak Consulting or Advisory Role: BeiGene, Lilly, Abbvie/Genentech, Takeda, Roche, AstraZeneca Research Funding: Roche, Takeda, Janssen-Cilag, BeiGene, AstraZeneca, Lilly, Abbvie/Genentech Dr. Jennifer Woyach Consulting or Advisory Role: Pharmacyclics, Janssen, AstraZeneca, Beigene, Loxo, Newave Pharmaceutical, Genentech, Abbvie, Merck Research Funding: Company name: Janssen, Schrodinger, beone, Abbvie, Merck, Loxo/Lilly Dr. Matthew Davids Honoraria: Curio Science, Aptitude Health, Bio Ascend, PlatformQ Health, Plexus Consulting or Advisory Role: Genentech, Janssen, Abbvie, AstraZeneca, Adaptive Biotechnologies, Ascentage Pharma, BeiGene, Lilly, Bristol-Myers Squibb, Genmab, Merck, MEI Pharma, Nuvalent, Inc., Galapagos NV, Schroedinger Research Funding: Ascentage Pharma, Novartis, MEI Pharma, AstraZeneca  

Die Talfahrt der HSG Wetzlar geht weiter. In Stuttgart kassierten die Handballer aus Mittelhessen die achte Pleite in Folge. Insgesamt war es sogar die elfte Pleite im 14. Saisonspiel für die Mittelhessen, die in der Tabelle weiter auf einem Abstiegsrang liegen. Die Folge: Nach Informationen des hr-sport steht Trainer Momir Ilic in Wetzlar zur Debatte. Am Sonntag gastiert die HSG zum Hessenderby bei der MT Melsungen. Außerdem: Raus aus dem Unterricht, rauf auf die Straße: In ganz Deutschland protestieren heute Schülerinnen und Schüler gegen den geplanten neuen Wehrdienst. Auch bei uns in Mittelhessen. In Friedberg gibt es am Mittag eine zentrale Kundgebung auf dem Elvis-Presley-Platz. In Marburg sind vormittags Aktionen an der Martin-Luther-Schule und am Schulzentrum in der Leopold-Lucas-Straße geplant. Später soll es eine Demo am Erwin-Piscator-Haus geben. Am Tag des Ehrenamts ist Udo Messer aus Friedberg besonders aktiv. Wir stellen vor, was der Rentner alles ehrenamtlich macht - und was ihn antreibt.

"Ich will nicht töten, Ich will eine Zukunft" - das steht auf ihren Pappschildern: Etwa 100 Menschen haben heute auf dem Elvis-Presley-Platz in Friedberg gegen das neue Wehrdienstgesetz demonstriert. Schülerinnen und Schüler aus der Wetterau, aber auch Eltern und solidarische Erwachsene. Viele der jungen Menschen, mit denen wir gesprochen haben, fühlen sich bei dem Thema unwohl, als würde die Bundesregierung ihnen ihre Selbstbestimmung wegnehmen. Für die Handballer der HSG Wetzlar sieht's in der Bundesliga gerade nicht sehr gut aus: Vorletzter in der Tabelle mit nur 5 Punkte aus 14 Spielen. Am Sonntag steht jetzt das Hessen-Derby gegen Melsungern an. Für Trainer Illic, ist es trotzdem ein Spiel wie jedes andere. Die Mannschaft soll kämpfen, hat er gegenüber dem hr gesagt. Außerdem: Im Prozess um einen der Betreiber des Untergrund-Drogenforums Crimenetwork hat der Angeklagte erstmals ausführlich gesprochen. Vor dem Landgericht in Gießen sagt der 30-jährige heute, er sei aus technischem Interesse in das Projekt eingestiegen. Das Forum sei „sein Baby“ gewesen. Geld habe am Anfang keine Rolle gespielt. Später aber sei daraus ein lukratives Geschäftsmodell geworden. Die Staatsanwaltschaft wirft ihm vor, keine echte Reue zu zeigen.

In Langgöns Dornholzhausen steht gestern Abend eine Scheune mitten in einem Wohngebiet lichterloh in Flammen. Verletzt wird niemand, laut ersten Schätzungen liegt der Schaden bei rund 100.000€. Ein klares Nein zu Gewalt an Frauen - das sagen heute Millionen Menschen auf der ganzen Welt - auch hier bei uns in Mittelhessen. Am Internationalen Tag zur Beendigung der Gewalt gegen Frauen liegen zum Beispiel in Friedberg und Bad Nauheim in Restaurants, Bars und Kneipen orangefarbene Bierdeckel mit Frauennotrufnummern aus. Ukrainekrieg, Nahostkonflikt, Klimawandel - zu solchen Themen wird auch in Uni-Hörsälen teilweise heftig diskutiert. Das neue EU-Projekt NAVINCLASS an der Uni Marburg will Lehrenden und Studierenden helfen, besser mit politischen Spannungen im Seminar umzugehen.

In Langgöns Dornholzhausen steht gestern Abend eine Scheune mitten in einem Wohngebiet lichterloh in Flammen. Verletzt wird niemand, laut ersten Schätzungen liegt der Schaden bei rund 100.000€. Ein klares Nein zu Gewalt an Frauen - das sagen heute Millionen Menschen auf der ganzen Welt - auch hier bei uns in Mittelhessen. Am Internationalen Tag zur Beendigung der Gewalt gegen Frauen liegen zum Beispiel in Friedberg und Bad Nauheim in Restaurants, Bars und Kneipen orangefarbene Bierdeckel mit Frauennotrufnummern aus. Ukrainekrieg, Nahostkonflikt, Klimawandel - zu solchen Themen wird auch in Uni-Hörsälen teilweise heftig diskutiert. Das neue EU-Projekt NAVINCLASS an der Uni Marburg will Lehrenden und Studierenden helfen, besser mit politischen Spannungen im Seminar umzugehen.

(0:00) Bestie intros LIVE from The Venetian Las Vegas (1:13) Epstein Files breakdown (10:06) Biggest Epstein questions: where did his money come from? (14:44) Tether's booming business (23:50) Michael Burry vs. Friedberg, Nvidia's blowout quarter and risks for 2026 (35:25) Google's Gemini 3 and TPU breakthrough (42:51) Investing your own money vs. LP capital, why Friedberg returned as a CEO (48:57) Alan Keating joins the show to talk poker strategy, thriving in chaos, risk psychology Special thanks to The Venetian Las Vegas for hosting us!: https://x.com/VenetianVegas Join us at the All-In Holiday Spectacular!: https://allin.com/events Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect Referenced in the show: https://x.com/RepClayHiggins/status/1990868089056219267 https://x.com/michaeljburry/status/1991289193037746579 https://polymarket.com/event/which-company-has-best-ai-model-end-of-2025 https://x.com/Similarweb/status/1988879389992386897 https://x.com/PokerGO/status/1987406318832132256

Gute Nachrichten vor dem Spiel am Freitag-Abend in Trier beim TSV Steinbach Haiger: Der Fußball-Regionalligist hat mit seinem Trainerteam verlängert. Das heißt, die beiden Trainer Daniel Wilde und Hüsni Tahiri bleiben dem Verein auch in der nächsten Saison erhalten. In Marburg gehen am Samstag Hebammen auf die Straße! Seit dem 1. November gilt der neue Hebammenhilfevertrag - der soll den Beruf der Hebamme attraktiver machen und eine 1:1 Betreuung belohnen. Die Demo soll aber darauf aufmerksam machen: Vor allem für Beleghebammen im Krankenhaus sieht die Realität oft anders aus - sie verdienen teilweise weniger als vorher. Angemeldet sind rund 300 Teilnehmende. Aber: Nicht alle Hebammen finden den neuen Vertrag schlecht. Für viele Freiberuflerinnen ist er tatsächlich eine Verbesserung - sie wollen sich aber auch solidarisch zeigen mit ihren Kolleginnen. Außerdem: Sie stehen seit 60 Jahren hinter ihrem Verkaufstresen in der Kaiserstraße in Friedberg. Marianne und Gerhard Ulrich in ihrem Traditionsgeschäft Steinöckel - eine Fundgrube für Jäger und Sportschützen. Hier werden vor allem Stahlwaren verkauft: Messer, Munition und Waffen. Nur: Einen Nachfolger haben die beiden noch nicht.

Gute Nachrichten vor dem Spiel am Freitag-Abend in Trier beim TSV Steinbach Haiger: Der Fußball-Regionalligist hat mit seinem Trainerteam verlängert. Das heißt, die beiden Trainer Daniel Wilde und Hüsni Tahiri bleiben dem Verein auch in der nächsten Saison erhalten. In Marburg gehen am Samstag Hebammen auf die Straße! Seit dem 1. November gilt der neue Hebammenhilfevertrag - der soll den Beruf der Hebamme attraktiver machen und eine 1:1 Betreuung belohnen. Die Demo soll aber darauf aufmerksam machen: Vor allem für Beleghebammen im Krankenhaus sieht die Realität oft anders aus - sie verdienen teilweise weniger als vorher. Angemeldet sind rund 300 Teilnehmende. Aber: Nicht alle Hebammen finden den neuen Vertrag schlecht. Für viele Freiberuflerinnen ist er tatsächlich eine Verbesserung - sie wollen sich aber auch solidarisch zeigen mit ihren Kolleginnen. Außerdem: Sie stehen seit 60 Jahren hinter ihrem Verkaufstresen in der Kaiserstraße in Friedberg. Marianne und Gerhard Ulrich in ihrem Traditionsgeschäft Steinöckel - eine Fundgrube für Jäger und Sportschützen. Hier werden vor allem Stahlwaren verkauft: Messer, Munition und Waffen. Nur: Einen Nachfolger haben die beiden noch nicht.

Recibimos de nuevo en nuestro estudio a una leyenda del rock más esencial de los sesenta, setenta y ochenta: Daniel “Freebo” Friedberg que ha tocado con Bonnie Raitt, Jackson Browne, Crosby Stills & Nash, etc y que viene acompañado de Alice Howe, cantante premiada recientemente en Nashville como mejor intérprete de folk-rock por su álbum “Americana Highways” grabado en los míticos estudios Fame de Muscle Shoals de Alabama. Han estado de gira por España y nos traen buenas nuevas y grandes canciones.DISCO 1 ALICE HOWE With You By My Side CircumstanceDISCO 2 ROBERT PLANT Everybody’s SongDISCO 3 SMITH & LIDDLE Minute AgoDISCO 4 KELLY JONES I’d Really Love To see You Tonight. MAMA ROSA +DISCO 5 BLUES AGAINST THE MACHINE Get Wild OnDISCO 6 FREEBO & ALICE HOWE She Loves My Dog More Than MeDISCO 7 ALICE HOWE & FREEBO Sailin’ ShoesDISCO 8 ALICE HOWE & FREEBO Angel From MontgomeryDISCO 9 ALICE HOWE & FREEBO A Case Of YouEscuchar audio

(0:00) Friedberg introduces 2025 Nobel Peace Prize Winner María Corina Machado (4:27) Venezuela before and after Chavez (15:25) Why María got involved in politics and why she was expelled (24:33) Why Maduro was chosen and Chavez's successor, China relationship, why people are fleeing (31:27) Intimidation tactics by the Maduro regime, response to claims of her being a "Western puppet" (39:30) Presidential run, election fraud, how different US regimes have viewed Venezuela (54:23) The rise of socialism in the US Follow María: https://x.com/MariaCorinaYA Learn more about the 2025 Nobel Peace Prize: https://www.nobelpeaceprize.org/articles/nobels-fredspris-2025-1 Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect

Am Kaufhaus Joh in Friedberg tut sich was, nach Jahren des Stillstands haben Bodenarbeiten begonnen, die den Abriss vorbereiten sollen. Außerdem wurde wieder ein Baum vergiftet. Dieses Mal ein Berg-Ahorn in Wetzlar-Niedergirmes

Am Kaufhaus Joh in Friedberg tut sich was, nach Jahren des Stillstands haben Bodenarbeiten begonnen, die den Abriss vorbereiten sollen. Außerdem wurde wieder ein Baum vergiftet. Dieses Mal ein Berg-Ahorn in Wetzlar-Niedergirmes

(0:00) Chamath and Friedberg welcome Andrew Ross Sorkin to discuss his new book, "1929: Inside the Greatest Crash in Wall Street History--and How It Shattered a Nation" (0:38) Why he chose this time period (3:22) The setup: what led to the 1929 crash (19:24) The characters: major players in the 1929 crash; what kind of bubble are we experiencing in 2025? (26:21) Role of journalist vs market participant; characters of the 2025 market (30:10) AI's potential 1929-like impact on unemployment (35:16) Why socialism is flaring up now more than it did post-1929 (40:34) Does the US need a 2025 "New Deal" on cutting spending, tariff balancing act (46:51) Film rights strategy Buy Sorkin's new book: https://www.amazon.com/1929-Inside-Greatest-History-Shattered/dp/0593296966 Follow Andrew Ross Sorkin: https://x.com/andrewrsorkin Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect Referenced in the show: https://www.amazon.com/1929-Inside-Greatest-History-Shattered/dp/0593296966 https://archive.org/details/sim_ladies-home-journal_1929-08_46_8/page/n9/mode/2up

Viele blinde Menschen nutzen einen weißen Langstock, um sich zu Fuß besser orientieren zu können - sie fühlen und hören damit, wo vor ihnen Hindernisse auf dem Weg sind. Heute ist internationaler Tag des weißen Stocks - und der hat seinen Ursprung an der Blindenstudienanstalt, kurz Blista, in Marburg. Wer tagsüber in den Himmel schaut, sieht sie mit hoher Wahrscheinlichkeit in ihrer typischen V-Formation. Tausende Kraniche sind wieder auf dem Weg in den Süden, um dort den Winter zu verbringen. Allein am Montag haben Ornithologen aus Marburg rund 20.000 Tiere über Hessen gezählt, die Richtung Frankreich unterwegs gewesen sind. Wer mag, keine seine Beobachtung dem Naturschutzbund NABU melden und so beim Zählen helfen. Im Achtelfinale des Fußball-Hessenpokals gibt es heute Abend ein Mittelhessen-Derby. Der Regionalligist TSV Steinbach Haiger trifft auf den Hessenligisten Türk Gücü Friedberg. Trotz des Ligenunterschieds dürfte es keine ausgemachte Sache sein, dass das Team aus Haiger gewinnt. Denn die Friedberger haben im vergangenen Jahr nur ganz knapp den Aufstieg in die Regionalliga verpasst.

Viele blinde Menschen nutzen einen weißen Langstock, um sich zu Fuß besser orientieren zu können - sie fühlen und hören damit, wo vor ihnen Hindernisse auf dem Weg sind. Heute ist internationaler Tag des weißen Stocks - und der hat seinen Ursprung an der Blindenstudienanstalt, kurz Blista, in Marburg. Wer tagsüber in den Himmel schaut, sieht sie mit hoher Wahrscheinlichkeit in ihrer typischen V-Formation. Tausende Kraniche sind wieder auf dem Weg in den Süden, um dort den Winter zu verbringen. Allein am Montag haben Ornithologen aus Marburg rund 20.000 Tiere über Hessen gezählt, die Richtung Frankreich unterwegs gewesen sind. Wer mag, keine seine Beobachtung dem Naturschutzbund NABU melden und so beim Zählen helfen. Im Achtelfinale des Fußball-Hessenpokals gibt es heute Abend ein Mittelhessen-Derby. Der Regionalligist TSV Steinbach Haiger trifft auf den Hessenligisten Türk Gücü Friedberg. Trotz des Ligenunterschieds dürfte es keine ausgemachte Sache sein, dass das Team aus Haiger gewinnt. Denn die Friedberger haben im vergangenen Jahr nur ganz knapp den Aufstieg in die Regionalliga verpasst.

Der hr ist rausgegangen - mit der „hessenschau“-Pop-Up-Redaktion mitten rein nach Friedberg auf die Kaiserstraße. Mehr als drei Wochen stehen Besucherinnen und Besucher im Zentrum - Redakteurinnen und Redakteure fragen nach ihrer Meinung, ihren Wünschen und Sorgen. Heute endet die Aktion. „Ein voller Erfolg“ bilanziert Andrea Seeger von der Evangelischen Kirche.

Jüdische Gemeinde in Gießen erhält neue 20 Kilo schwere Tora. Die hr Pop-Up Redaktion in Friedberg zieht nach knapp drei Wochen Bilanz.

In Gießen wird das Fahrradfahren immer beliebter. Von Januar bis Juli wurden laut Verwaltung in diesem Jahr fast 200.000 Fahrten mit dem städtischen Leihradsystem gezählt - das ist ein Anstieg um 18 Prozent im Vergleich zum Vorjahr. Mobbing und Gewalt - oder sogar sexueller Missbrauch - all das können im schlimmsten Fall Probleme im Schulalltag sein. In Hüttenberg im Lahn-Dill-Kreis gibt es jetzt eine neue Anlaufstelle für Kinder, Jugendliche und Familien. Der Verein "Wir für dich - Hüttenberg" bietet kostenlose Beratung und Kontakte zu weiteren Hilfsangeboten an. Es ist ein kleiner Pieks in den Oberarm, der aber Schlimmeres verhindern kann: Weil gerade wieder die Grippe- und Corona-Saison losgegangen ist, hat der Apothekerverband die lange Nacht des Impfens ausgerufen. Viele Apotheken beteiligen sich daran - zum Beispiel in der Hauptapotheke im Ärztehaus am Wetzlarer Klinikum, die Apotheke an der hohen Leuchte in Marburg und die Liebig-Apotheke in Friedberg.

In Gießen wird das Fahrradfahren immer beliebter. Von Januar bis Juli wurden laut Verwaltung in diesem Jahr fast 200.000 Fahrten mit dem städtischen Leihradsystem gezählt - das ist ein Anstieg um 18 Prozent im Vergleich zum Vorjahr. Mobbing und Gewalt - oder sogar sexueller Missbrauch - all das können im schlimmsten Fall Probleme im Schulalltag sein. In Hüttenberg im Lahn-Dill-Kreis gibt es jetzt eine neue Anlaufstelle für Kinder, Jugendliche und Familien. Der Verein "Wir für dich - Hüttenberg" bietet kostenlose Beratung und Kontakte zu weiteren Hilfsangeboten an. Es ist ein kleiner Pieks in den Oberarm, der aber Schlimmeres verhindern kann: Weil gerade wieder die Grippe- und Corona-Saison losgegangen ist, hat der Apothekerverband die lange Nacht des Impfens ausgerufen. Viele Apotheken beteiligen sich daran - zum Beispiel in der Hauptapotheke im Ärztehaus am Wetzlarer Klinikum, die Apotheke an der hohen Leuchte in Marburg und die Liebig-Apotheke in Friedberg.

Episode 228 NPTEFF Interview with David Friedberg, PT, DPT

(0:00) Introducing Cleo Abram (1:12) Why YouTube has become the best platform for creators, techno-optimism at Huge If True (8:35) Astrophysicist Alex Filippenko on the James Webb Space Telescope (23:14) Q&A with Alex Filippenko, Cleo, and Friedberg: The universe, Fermi Paradox, black holes, NIH grants and the “war on science” (37:37) Zipline CEO Keller Rinaudo Cliffton on the future of drone delivery (53:29) Q&A with Keller Rinaudo Cliffton, Cleo, and Friedberg: Instant delivery explosion, competitors, impact on healthcare Thanks to our partners for making this happen! Solana - Solana is the high performance network powering internet capital markets, payments, and crypto applications. Connect with investors, crypto founders, and entrepreneurs at Solana's global flagship event during Abu Dhabi Finance Week & F1: https://solana.com/breakpoint OKX - The new way to build your crypto portfolio and use it in daily life. We call it the new money app. https://www.okx.com/ Google Cloud - The next generation of unicorns is building on Google Cloud's industry-leading, fully integrated AI stack: infrastructure, platform, models, agents, and data. https://cloud.google.com/ IREN - IREN AI Cloud, powered by NVIDIA GPUs, provides the scale, performance, and reliability to accelerate your AI journey. https://iren.com/ Oracle - Step into the future of enterprise productivity at Oracle AI Experience Live. https://www.oracle.com/artificial-intelligence/data-ai-events/ Circle - The America-based company behind USDC — a fully-reserved, enterprise-grade stablecoin at the core of the emerging internet financial system. https://www.circle.com/ BVNK - Building stablecoin-powered financial infrastructure that helps businesses send, store, and spend value instantly, anywhere in the world. https://www.bvnk.com/ Polymarket - https://www.polymarket.com/ Follow Cleo: https://x.com/cleoabram https://www.youtube.com/c/CleoAbram Follow Keller: https://x.com/keller Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg

Die heimische Presse rümpfte damals die Nase über den Riesenwirbel, als der frenetisch verehrte Schwarm und King of Rock'n Roll in der US-Kaserne Ray Barracks in Friedberg ankam, um dort seinen Militärdienst abzuleisten.Elvis Presley war dort von Oktober 1958 bis März 1960 stationiert.

SEASON 2 - EPISODE 160 - Mark Friedberg - Production Designer In this extended (and funny) episode of the Team Deakins Podcast, we speak with production designer Mark Friedberg (CAUGHT STEALING, JOKER, THE UNDERGROUND RAILROAD). A native New Yorker, it wasn't until returning to the city after Jack Kerouac-ing around the country that Mark (and his dog) first found work in the film industry as a driver for the Woody Allen production team. Mark was eventually let out of the van, and, throughout our conversation, he reveals how he thought through many of the challenges in his long and impressive career as a designer. Mark is also a staple in Barry Jenkins' (Season 2, Episode 156) stable of collaborators, and we learn how Mark's daughter convinced her father to break his own rules to initially meet with the director. We also discuss technology's place in Mark's design process, and he shares why he rehired the millennial gamers who built MUFASA's Africa to digitally visualize the sets of JOKER: FOLIE À DEUX before physically constructing them.  - Recommended Viewing: THE ICE STORM - This episode is sponsored by Sandstorm & Aputure

Tim and Tyler talked with David Friedberg last year about joining Ohalo, lessons from The Climate Corp, and what will in in ag. — This episode is presented by American AgCredit. Check them out HERE. — Links Ohalo - https://www.ohalo.com Climate Corp Podcast - https://www.themodernacre.com/302-the-story-of-the-climate-corporation/ YouTube Channel - https://www.youtube.com/@themodernacre

Anna F. of Friedberg joins us to talk about the band's debut album, Hardcore Workout Queen, and why the cowbell is her favorite instrument. Plus, Friedberg performs live.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Sandra Weihs: Bemühungspflicht | Frankfurter Verlagsanstalt 2025 | Preis: 24 Euro Von der hr2-Partnerbuchhandlung „Bindernagel“ in Friedberg

Sandra Weihs: Bemühungspflicht | Frankfurter Verlagsanstalt 2025 | Preis: 24 Euro Von der hr2-Partnerbuchhandlung „Bindernagel“ in Friedberg

International Mortgage Solutions For Canadians - Jeremy Friedberg   Jeremy Friedberg, who runs an alternative financing company for Canadians called Seaport Credit Canada, flew all the way from Cancun Mexico to join me for an unscripted chat about alternative financing! Seaport helps Canadians by providing alternative financing solutions to Canadians purchasing real estate outside Canada. They also help Canadians access flexible funding for property investments around the world. Jeremy breaks down the basics of alternative international real estate financing, and how Seaport is helping Canadians to invest abroad, with financing backed by their RRSPs, and MORE, so TUNE IN!   Plus Gary's Tip Of The Week! Contact:  jfriedberg@seaportcredit.com  SeaportCredit.com  Exciting News! Real Talk With Gary - Real Estate Investing has been recognized as one of the Top 45 Canada Real Estate Podcasts by MillionPodcasts! This list highlights the most comprehensive and respected real estate podcasts across the country, and I'm honoured to be featured alongside some of the best in the industry. Check out the full list here:

Um auf das 90er Festival in Friedberg zu kommen, musste man sich erst dem ultimativen 90er Quiz vom Dummfrager stellen.

(0:00) Friedberg and Chamath welcome Senator Ron Johnson (2:30) The Reconciliation Bill process, how much the Big, Beautiful Bill will add to the national debt (14:33) Problems with growing our way out of debt, why elected officials are avoiding the fiscal reality (24:53) Energy rescissions, future of DOGE (32:09) How Senator Johnson will force a real review of the Big, Beautiful Bill; future of MAGA and the Conservative movement (54:15) Next steps if the Big, Beautiful Bill passes (58:35) Post-interview recap Follow Senator Johnson: https://x.com/RonJohnsonWI Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect

Dans un contexte mondial secoué par les crises sanitaires, les tensions géopolitiques et les mutations économiques, la logistique s'impose plus que jamais comme un maillon stratégique du commerce international et du développement des territoires. À l'occasion de l'Africa CEO Forum 2025, rendez-vous des décideurs privés africains et internationaux, Mathieu Friedberg, directeur général de Ceva Logistics et membre du comité exécutif de CMA CGM est notre Grand Invité de l'Économie avec Bruno Faure (RFI) et  Aurélie M'Bida, cheffe du pôle économie de Jeune Afrique. Peu connu du grand public, Ceva Logistics pèse pourtant lourd : présent dans 170 pays, employant plus de 110 000 collaborateurs et récemment renforcé par l'acquisition de Bolloré Logistics. À travers cet entretien exclusif, Mathieu Friedberg revient sur son parcours, de ses débuts chez CMA CGM à la direction de CEVA Logistics, et décrypte les grands enjeux de son secteur : infrastructures insuffisantes, défis sécuritaires, adaptation aux contraintes fiscales et réglementaires africaines, mais aussi digitalisation, automatisation et décarbonation du fret mondial.Alors que l'Afrique représente un marché de croissance prioritaire, ce spécialiste des chaînes d'approvisionnement explique comment son groupe accompagne la mise en œuvre de la Zone de libre-échange continentale africaine (ZLECAF) et développe des solutions sur-mesure pour connecter les économies africaines entre elles et au reste du monde.En fin d'émission, nous donnons la parole à deux candidats à la présidence de la Banque africaine de développement qui organise fin mai ses Assemblées générales à Abidjan.- la Sud-africaine Bajabulile Swazi Tshabalala, ancienne première vice-présidente de la BAD- le Zambien Samuel Munzele Maimbo, ancien vice-président du budget et de la planification stratégique à la Banque mondiale

In this episode, Jason chats with David Friedberg—CEO of Ohalo Genetics and co-host of the All-In Podcast—about how AI is transforming agriculture and startups. David introduces Ohalo's "Boosted Breeding" technology, which enables plants to inherit 100% of genes from both parents, potentially doubling crop yields. They also discuss building AI-first companies, genome language models, and the future of creativity in an AI-driven world.*Timestamps:(0:00) David Friedberg joins Jason to discuss AI Basics.(1:44) How AI leveled up hiring and operations at startups(5:46) AI and economic opportunities, complex problem-solving, and leadership's role(11:48) How to build an AI-first company culture(16:48) AI's transformative impact on biology and DNA sequencing(21:36) The “GLM” - GPT for DNA Is already in production(23:17) Biology meets AI: designing perfect plants with CRISPR and genome models(32:08) Is the “Age of Abundance” around the corner?(35:56) Democratization of creativity through AI: personalized Star Wars musicals & the future of media*Uncover more valuable insights from AI leaders in Google Cloud's 'Future of AI: Perspectives for Startups' report. Discover what 23 AI industry leaders think about the future of AI—and how it impacts your business. Read their perspectives here: https://goo.gle/futureofai*Check out all of the Startup Basics episodes here: https://thisweekinstartups.com/basicsCheck out Google Cloud: https://cloud.google.com/Check out Ohalo: https://www.ohalo.com/*Follow David:X: https://x.com/friedbergLinkedIn: https://www.linkedin.com/in/davidfriedberg/*Follow Jason:X: https://twitter.com/JasonLinkedIn: https://www.linkedin.com/in/jasoncalacanis*Follow TWiST:Twitter: https://twitter.com/TWiStartupsYouTube: https://www.youtube.com/thisweekinInstagram: https://www.instagram.com/thisweekinstartupsTikTok: https://www.tiktok.com/@thisweekinstartupsSubstack: https://twistartups.substack.com

Today on Moment of Zen, we're sharing a conversation about rebuilding American manufacturing recorded at this week's Hill & Valley Forum in Washington D.C. Senator Todd Young is joined by Shaun Maguire, a partner at Sequoia, and David Friedberg the CEO of Ohalo to discuss the massive energy gap with China, how to reform education for industrial jobs, and where strategic innovation could help the US regain its competitive edge. If you're interested to hear all the talks from the forum, please subscribe to The Hill & Valley Forum Podcast: ⁠YouTube: https://www.youtube.com/@HillValleyForum⁩⁠ Apple:⁠ https://podcasts.apple.com/us/podcast/the-hill-valley-forum-podcast/id1692653857⁠ Spotify: ⁠https://open.spotify.com/show/39s4MCyt1pOTQ8FjOAS4mi⁠ --

Catching up with Dan Pritchard in Australia, and we hear about his life in the country, things that are different there, human things that are a constant wherever you go, and a bit about Brown snakes. Music at the end from Friedberg with The Greatest.

(0:00) The Besties welcome Tim Dillon! (6:56) Nvidia H20 export controls, the China workaround, plausible deniability by chipmakers selling to China-linked entities (28:45) Trump vs. Harvard: Why the White House is threatening to take Harvard's tax-exempt status away (57:04) Hollywood's DEI facade, thoughts on AI, and more (1:18:06) Celebrity Jeopardy update: Friedberg is heading to the finals! (1:26:44) Science Corner: Mitochondrial Therapy Follow Tim: https://x.com/TimJDillon Check out Tim's new special: https://www.netflix.com/title/81992010 Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect Referenced in the show: https://www.youtube.com/watch?v=wUzmVo2dZNs https://www.wsj.com/livecoverage/stock-market-trump-tariffs-trade-war-04-15-25/card/nvidia-records-5-5-billion-charge-on-new-h20-export-restrictions-LXjxlqr2m80QIrfJxnYZ https://www.wsj.com/economy/trade/trump-chip-exports-nvidia-h20-china-amd-d2c4c866 https://www.reuters.com/technology/exclusive-nvidia-offers-new-advanced-chip-china-that-meets-us-export-controls-2022-11-08 https://abachy.com/news/nvidia-unveil-new-ai-chips-chinese-market-after-us-bans-a800-and-h800 https://www.moomoo.com/community/feed/compared-to-the-h100-how-is-the-performance-of-the-111725151846805 https://www.reuters.com/technology/tsmc-could-face-1-billion-or-more-fine-us-probe-sources-say-2025-04-08 https://www.bis.gov https://www.cnbc.com/2025/04/15/us-is-unable-to-replace-rare-earths-supply-from-china-warns-csis-.html https://www.bloomberg.com/news/articles/2025-03-31/trump-administration-to-review-billions-in-grants-to-harvard https://www.harvard.edu/research-funding/wp-content/uploads/sites/16/2025/04/Letter-Sent-to-Harvard-2025-04-11.pdf https://www.harvard.edu/president/news/2025/the-promise-of-american-higher-education https://apnews.com/article/harvard-trump-administration-federal-cuts-antisemitism-0a1fb70a2c1055bda7c4c5a5c476e18d https://www.cnn.com/2025/04/16/politics/irs-harvard-tax-exempt-status/index.html https://www.boston.com/news/local-news/2024/09/05/harvard-comes-in-dead-last-in-nationwide-free-speech-rankings https://en.wikipedia.org/wiki/Bob_Jones_University_v._United_States https://en.wikipedia.org/wiki/Students_for_Fair_Admissions_v._Harvard https://www.thecrimson.com/article/2022/7/13/faculty-survey-political-leaning https://www.reuters.com/world/europe/ukraines-parliament-extends-martial-law-until-august-2025-04-16 https://www.nature.com/articles/s41586-023-06537-z https://www.nature.com/articles/d41586-025-00848-z https://www.researchgate.net/publication/389907980_Organelle-tuning_condition_robustly_fabricates_energetic_mitochondria_for_cartilage_regeneration/fulltext/67d8575e478c5a3feda50563/Organelle-tuning-condition-robustly-fabricates-energetic-mitochondria-for-cartilage-regeneration.pdf https://www.foxnews.com/media/george-clooney-calls-breaking-biden-2024-his-civic-duty-says-democrats-werent-telling-truth

(0:00) Friedberg and Jason are live from Austin! (2:51) How building an audience has impacted the Besties (11:15) Colin & Samir join the Besties! (12:01) Evolution of short-form and long-form content (22:18) Business models for creatives (35:04) Advice to up and coming creators (42:10) Chris Williamson joins the Besties! (50:17) Making it seem effortless (57:47) Monetizing content (1:05:02) Scaling a one-man show (1:19:15) Bryan Johnson joins the Besties! (1:20:13) Spotify's move to video (1:21:21) Bryan's Ketamine experience (1:28:03) Creators and value props (1:36:52) Issues with the US food industry (1:43:10) Top tips for healthy living Thanks to our partners for making this happen: Gemini: Go to https://www.gemini.com/allin to get $50 in bitcoin when you sign up and trade. Function Health: Go to https://www.functionhealth.com/allin and use gift code ALLIN100 at checkout to get a $100 credit toward membership - limited to the first 1K listeners. NIAGEN Plus IVs: Visit https://www.niagenplus.com to discover the future of cellular performance. Follow Colin and Samir: https://www.youtube.com/@ColinandSamir https://x.com/ColinandSamir Follow Chris Williamson: https://www.youtube.com/@ChrisWillx https://x.com/ChrisWillx Follow Bryan Johnson: https://www.youtube.com/@BryanJohnson   https://x.com/bryan_johnson Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect

(0:00) Chamath and Friedberg welcome Commerce Secretary Howard Lutnick! (1:10) Howard describes his 30+ year relationship with President Trump and his road from business to politics (14:44) Running Trump's transition team, DOGE origin story, what it's like working for Trump (38:01) Balancing the budget and fixing GDP (52:21) Tariff history and strategy, global trade (1:10:34) Trump Cards, building better government software, AI thoughts (1:22:49) Sovereign Wealth Fund strategy (1:37:16) How his family reacted to his new role Thanks to our partners for making this happen: Gemini: https://www.gemini.com/allin Hims: https://www.hims.com | https://www.forhers.com iTrustCapital (use code allin): https://www.itrustcapital.com/allin Follow Secretary Lutnick: https://x.com/howardlutnick Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect

(0:00) Chamath and Friedberg describe their adventures in DC and welcome Treasury Secretary Scott Bessent! (2:12) Scott's background, what drew him to equities, the role of macro investors (7:22) The legendary trade that broke the Bank of England in 1992, and how it relates to Main Street vs Wall Street today (21:30) Scott explains the Trump Administration's economic strategy (32:45) How this administration plans to de-regulate the economy, Fed relationship, re-financing debt (42:06) DOGE, DC grifts, shakeup at the IRS (50:51) Re-engineering social security through the US SWF, how energy factors in (1:00:02) Surprises, fixing affordability, thoughts on President Trump Thanks to our partners for making this happen: Hims: https://www.hims.com | https://www.forhers.com iTrustCapital (use code allin): https://www.itrustcapital.com Follow Secretary Bessent: https://x.com/SecScottBessent Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect

(0:00) The Besties intro Andrew Schulz! (3:29) Friedberg hits a quick Science Corner on the future of fertility (9:35) Reacting to Gavin Newsom's new podcast: genius or pandering? (19:36) Tariff experiment so far: risks, communication issues, and more (30:44) Why the American Dream is broken and how to fix it: cracking the housing market, social security reform (55:45) Aligning upside via increased stock market participation (1:11:23) How Andrew blew up in comedy, going direct via YouTube, building a cancel-proof following (1:22:25) State of America, conspiracy obsession, thoughts on Trump and DOGE GET TICKETS for All-In Live: Miami https://allin.com/events Follow Andrew: https://x.com/andrewschulz Check out Andrew's new special LIFE: https://www.netflix.com/title/81741999 Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect Referenced in the show: https://x.com/chamath/status/1895948351516131515 https://x.com/ChineseEmbinUS/status/1897132043362034153 https://electrek.co/2025/02/07/renewables-90-percent-new-us-capacity-2024-ferc https://www.wsj.com/opinion/bidens-mortgage-relief-fuels-higher-housing-prices-policy-loans-risk-cb0a1974

Welcome back to the I Give a Sh*t About My Employees podcast! Today, we're sitting down with Rose Jones, the Director of Human Resources at Meyers, Roman, Friedberg & Lewis, a company that has won Culture Awards year after year.

(0:00) Bestie intros (1:41) Epstein files first release underwhelms (4:40) Friedberg recaps his experience on Celebrity Jeopardy! (14:22) State of autonomous robots (21:06) Comparing annual reports from Stripe and Adyen; Stripe's network effects, stablecoin infra, and the pace of AI company building (29:12) State of the market: stocks, tariffs, spending bill, the "great reset" (49:07) Trump's Gold Card (56:19) Sophisticated investor test, changing accreditation laws (1:06:57) USPS, Bezos refocuses the WaPo's opinion page Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn:  https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect Referenced in the show: https://x.com/bennyjohnson/status/1895195194947183047 https://x.com/adcock_brett/status/1895175400160133543 https://x.com/markjeffrey/status/1892735775550406828 https://x.com/pitdesi/status/1895117427480109238 https://x.com/jmover/status/1895129169882661100 https://coinmarketcap.com/currencies/tether https://coinmarketcap.com/currencies/usd-coin https://fred.stlouisfed.org/series/UNRATE https://www.cnbc.com/2025/02/12/cpi-january-2025.html https://x.com/StealthQE4/status/1894227465616171361 https://www.youtube.com/watch?v=7-ttACozP8s https://www.cnbc.com/quotes/US10Y https://x.com/chamath/status/1888371069322686895 https://polymarket.com/event/how-many-gold-cards-will-trump-sell-in-2025/will-trump-sell-2pt5k-5k-gold-cards-in-2025?tid=1740688723350 https://x.com/Jason/status/1706067572226244789 https://www.washingtonpost.com/business/2025/02/20/trump-usps-takeover-dejoy/ https://x.com/Jason/status/1894412028279693546 https://x.com/JeffBezos/status/1894757287052362088

(0:00) Ray Dalio joins Friedberg! (0:50) The current US fiscal situation (6:23) Breaking down "The Big Debt Cycle," a potential US debt spiral, and the impact on real wealth (24:54) USD vs other currencies and assets, best hedges against the dollar (33:20) Portfolio construction, how China increases risk for US AI companies, why this market reminds Ray of 1998-1999 (41:45) How the US can avoid a debt crisis (53:29) DOGE, Trump, and AI's greatest risk (1:05:31) Chances of conflict between the US and China Follow the Besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow Ray Dalio: https://x.com/RayDalio Read Part 1 of "How Countries Go Broke": https://x.com/RayDalio/status/1878840018770210979 Pre-order "How Countries Go Broke": https://www.amazon.com/Principles-Investment-Economic-Ray-Dalio/dp/1501124064 Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect Referenced in the show: https://tradingeconomics.com/united-states/government-debt-to-gdp https://www.crfb.org/press-releases/treasury-confirms-calendar-year-2024-deficit-tops-20-trillion https://www.cbo.gov/publication/61172 https://www.institutionalinvestor.com/article/2bstne1l09npgdk1s5yww/corner-office/ray-dalio-makes-his-exit-from-bridgewater https://fred.stlouisfed.org/series/M2SL https://www.jpmorgan.com/insights/outlook/economic-outlook/fed-meeting-september-2024 https://www.forbes.com/sites/robertfarrington/2024/11/08/fed-cut-interest-rates-so-why-do-mortgage-rates-keep-climbing https://www.chathamfinancial.com/insights/fomc-recap-december-2024 https://www.cnbc.com/2025/01/14/a-global-bond-sell-off-is-deepening-as-hopes-for-multiple-fed-rate-cuts-fizzle.html

(0:00) Announcement from Friedberg (0:18) Besties intro JD Vance! (3:33) America's innovation problem (5:04) Thoughts on Trump (8:53) Would JD Vance have certified the election in 2020? (12:02) Increasing government efficiency, shrinking the deficit, Vance's role as VP, thoughts on EOs (19:35) Political realignment: Dick Cheney endorses Kamala Harris, winners and losers of the last 30 years (23:58) Thoughts on Lina Khan clamping down on tech M&A and her impact on the startup ecosystem (25:55) Fixing the Southern Border (32:16) How to practically approach deportations, who's coming in through the Southern Border? (36:51) Relationship with China Follow JD Vance: https://x.com/JDVance Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect

(0:00) Announcement from Friedberg (0:20) Besties intro Elon Musk! (4:19) The Battle of Free Speech (13:21) Potential government efficiency agency (30:41) SpaceX updates, overreaching regulations (39:06) Thoughts on Boeing's culture (41:23) The 80/20 AI Future (56:59) Elon and Jason share unaired SNL skits Intro song credit: M83 - Outro Follow Elon: https://x.com/elonmusk Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect

(0:00) Announcement from Friedberg! (0:21) Sacks intros John Mearsheimer and Jeffrey Sachs (1:32) What is the Deep State Party, and what are their goals? (13:56) Should America leverage its power against dictators? (22:07) The China threat: avoiding the escalatory path to nuclear war (36:08) India's growing role; are China's wounds self-inflicted? (47:07) Conflict in the Middle East and the path to peace Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect